
We connect science and compassion to reimagine mental health care.
COMPASS Pathways is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is developing COMP360 psilocybin therapy, currently in Phase 3 clinical trials for treatment-resistant depression, as well as studies for PTSD and anorexia nervosa. Listed on Nasdaq as CMPS, COMPASS holds FDA Breakthrough Therapy designation for its lead candidate.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountCreate a free account to see full funding history, valuations, and investor participation.
Create Free AccountCreate a free account to see which investors have funded this company.
Create Free Account